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Abstract
Orthotopic bladder cancer xenografts are essential for testing novel therapies and molecular manipulations of cell lines
in vivo. Current xenografts rely on tumor cell inoculation by intravesical instillation or direct injection into the bladder wall.
Instillation is limited by the lack of cell lines that are tumorigenic when delivered in this manner. The invasive model inflicts
morbidity on the mice by the need for laparotomy and mobilization of the bladder. Furthermore this procedure is complex
and time-consuming. Three bladder cancer cell lines (UM-UC1, UM-UC3, UM-UC13) were inoculated into 50 athymic nude
mice by percutaneous injection under ultrasound guidance. PBS was first injected between the muscle wall and the mucosa
to separate these layers, and tumor cells were subsequently injected into this space. Bioluminescence and ultrasound were
used to monitor tumor growth. Contrast-enhanced ultrasound was used to study changes in tumor perfusion after systemic
gemcitabine/cisplatin treatment. To demonstrate proof of principle that therapeutic agents can be injected into established
xenografts under ultrasound guidance, oncolytic virus (VSV) was injected into UM-UC3 tumors. Xenograft tissue was
harvested for immunohistochemistry after 23–37 days. Percutaneous injection of tumor cells into the bladder wall was
performed efficiently (mean time: 5.7 min) and without complications in all 50 animals. Ultrasound and bioluminescence
confirmed presence of tumor in the anterior bladder wall in all animals 3 days later. The average tumor volumes increased
steadily over the study period. UM-UC13 tumors showed a marked decrease in volume and perfusion after chemotherapy.
Immunohistochemical staining for VSV-G demonstrated virus uptake in all UM-UC3 tumors after intratumoral injection. We
have developed a novel method for creating orthotopic bladder cancer xenograft in a minimally invasive fashion. In our
hands this has replaced the traditional model requiring laparotomy, because this model is more time efficient, more precise
and associated with less morbidity for the mice.
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Introduction
Bladder cancer is the fourth most common cancer in men and
the ninth most common cancer in women in developed countries
[1]. In 2010 there were 70,530 incident cases and 14,680 deaths
from bladder cancer in the U.S. [2]. Approximately three quarters
of cases are non-muscle invasive [3]. These have a high propensity
for recurrence and a subset is at risk for progression to invasive
disease [4]. The remaining one quarter of cases present as muscle
invasive bladder cancer. Despite optimal multimodal therapy,
approximately one half of patients with muscle invasive bladder
cancer will succumb to their disease [5]. No significant break-
throughs have been made in the past two decades to enhance the
systemic therapy of this patient population [6].
Murine models of human cancer using cell lines derived from
patient tumors (xenografts) are an essential tool in cancer research.
They allow us to interrogate tumor biology with molecular
manipulation, to identify relevant diagnostic and predictive
biomarkers, and to test antineoplastic effects of novel therapies.
For bladder cancer, inoculation of human cell lines into the mouse
bladder (orthotopic xenograft) is the reference standard [7,8]. This
inoculation can be achieved either by intravesical instillation of
tumor cells (‘‘intravesical model’’) [9] or direct injection into the
bladder wall (‘‘intramural model’’) [10]. Alternative models
include the inoculation of murine bladder cancer cells in
immunocompetent mice (syngeneic model) [11] as well as
transgenic models [12]. Similar models are also possible in rats
[13,14].
Each orthoptic xenograft model has its shortcomings. Intrave-
sical instillation leads to the formation of tumors on the urothelial
surface of the bladder that are amenable to subsequent intravesical
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extraordinarily challenging using this method to achieve reliable
tumor take with any cell lines other than KU7 [9], which we have
recently demonstrated to be HeLa [15]. Furthermore, intravesical
cell inoculation is time consuming and can lead to uncontrolled
tumor growth in adjacent organs (urethra, ureter, renal pelvis)
[16]. Finally, tumor location within the bladder is unpredictable,
such that growth around the ureteral orifices can cause severe
upper tract obstruction before mice reach therapeutic endpoints.
Direct injection of tumor cell into the bladder wall leads to the
formation of invasive bladder tumors that are suitable for systemic
treatments [10]. Although several cell lines grow reliably as
xenografts in this model, the application is limited by the
morbidity inflicted on the mice by the need for laparotomy and
mobilization of the bladder [17]. It is also technically challenging
to ensure adequate injection into the bladder wall, and this
method is associated with a significant learning curve.
We have developed a novel approach to address these
limitations of the intramural inoculation of bladder cancer
xenografts, and thereby potentially enhance the accuracy and
reproducibility of this model. We have optimized the percutane-
ous, ultrasound-guided injection of bladder cancer cells into the
anterior bladder wall. In addition, we are able to monitor
xenograft growth and perfusion in vivo longitudinally during
therapy [18,19], and we are able to inject therapeutic agents
directly into the tumor under ultrasound guidance. Here we
demonstrate the feasibility and reproducibility of ultrasound-
guided intramural inoculation of orthotopic bladder cancer
xenografts as well as subsequent image guided manipulation and
monitoring.
Materials and Methods
Animals
Fifty 10-week-old female athymic nude mice were purchased
from Harlan (Indianapolis, IN, USA). All animal procedures were
performed according to the guidelines of the Canadian Council on
Animal Care (CCAC). The protocol was approved by the Animal
Care Committee of the University of British Columbia (Protocol
Number: A10-0192).
Tumor Cell Lines
The human bladder cancer cell lines UM-UC1, UM-UC3 and
UM-UC13 were kindly provided by the Pathology Core of the
Bladder Cancer SPORE at MD Anderson Cancer Center
(Houston, TX, USA) [20–22]. Cell line identities were confirmed
by DNA fingerprinting using the AmpFlSTRH IdentifilerH
Amplification protocol (Applied Biosystems, Carlsbad, CA, USA)
[23]. All cell lines were cultured for less than 3 months in
Dulbecco’s modified Eagle’s medium (DMEM) with 10% fetal
bovine serum (FBS) at 37uC in a humidified 5% CO2 atmosphere.
For in vivo studies, the cell lines underwent transduction with
a lentiviral construct carrying the luciferase firefly gene for in vivo
imaging [9]. The luciferase plasmid contained a blasticidin
resistance gene enabling positive selection with 10 mg/mL
blasticidin (Invitrogen, Life Technologies Inc., Burlington, ON,
Canada). Cell lines were controlled for in vitro luciferase activity
and cell number was correlated with bioluminescence (R.0.99;
data not shown), using the Xenogen IVIS Spectrum (Caliper
Lifesciences, Hopkinton, MA, USA). For xenograft studies the
cells were harvested at 70% confluence and suspended in
MatrigelH (BD Biosciences, Mississauga, ON, Canada). The cell
concentration was modified based on previously established
growth kinetics of the three different cell lines (UM-UC1 luc
9610
6/mL; UM-UC3 luc 12610
6/mL; UM-UC13 luc 11610
6/
mL).
Percutaneous Tumor Inoculation
Tumor inoculation was performed with the Vevo 770H small
animal imaging platform (Visual Sonics, Toronto, ON, Canada).
A high frequency RMV 706 ultrasound scanhead (20–60 MHz),
which allowed a lateral resolution of 30 micron and frame rates up
to 240 fps, was used.
The mice were anesthetized with isoflurane and mounted on the
imaging table with continuous monitoring of vital signs [Fig. 1A].
The abdomen was disinfected with alcohol and sterile ultrasound
gel was applied. The bladder was visualized on the screen [Fig. 1B]
and the bladder lumen was filled with sterile, warm phosphate-
buffered saline (PBS) through a 24 gauge angiocatheter to a desired
volume of 50–100 mL.
A 1.0 mL syringe filled with PBS and connected to a 30 gauge,
L inch needle (Kendall, Mansfield, MA, USA) was brought to the
skin just above the pubic bone at an angle of 30u with the bevel
directed anteriorly. After detection of the needle on the ultrasound
screen [Fig. 2A], it was passed through the skin and the abdominal
wall muscles [Fig. 2B]. The bevel of the needle was turned 180u
(directed posteriorly) before the tip was inserted into the bladder
wall without penetration of the mucosa [Fig. 2C]. PBS (50 mL) was
injected between the muscular layer and the mucosa to create
a space [Fig. 2D] and the needle was withdrawn. A second 1.0 mL
syringe (filled with cancer cells suspended in MatrigelH, (BD
Biosciences)) with a 30 gauge, L inch needle was guided into the
same space [Fig. 2E]. 40 mL (UM-UC1 luc) or 50 mL(UM-UC3
luc, UM-UC13 luc) of the cell suspension were injected into this
space [Fig. 2F].
In two additional mice agarose was injected in a similar fashion
in order to establish the exact location of xenograft inoculation
within the bladder wall. The mice were immediately sacrificed and
their bladders were removed for histologic analysis.
Xenograft Growth Monitoring
Tumor growth was monitored by bioluminescence imaging
(BLI) and ultrasound every third day starting 4 days after tumor
inoculation. The Xenogen IVIS system was used for BLI and mice
were imaged 10 and 15 minutes after intraperitoneal injection of
D-Luciferin (150 mg/kg bodyweight; Firefly, Caliper Life Sci-
ence). 3D ultrasound was performed in anesthetized mice with
scanning of the bladder as a whole in 0.1 mm steps. The tumor
volume was determined using the Visual Sonics imaging software
package by analysis of every fifth picture according to the user
manual [24].
Microbubble Contrast-Enhanced Ultrasound Analysis of
Tumors
To visualize the perfusion status of the xenograft tumors, a cine
loop was recorded as the reference. A second cine loop (1000
frames at 30 Hz) was recorded 10 seconds after injection of
120 mL non-targeted microbubbles (Visual Sonics) into the tail
vein of anesthetized mice. The point at which microbubbles
entered the plane was determined and the background reference
was subtracted. The tumor was selected as the contrast region and
Reference Subtracted Mean Data were used. Changes of the
Contrast Percent Area over time were documented and 2D images
were recorded in which any pixel was marked green when
a microbubble passed [24].
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PLOS ONE | www.plosone.org 2 March 2013 | Volume 8 | Issue 3 | e59536Figure 1. Ultrasound imaging. A. The mice were anesthetized with isoflurane and mounted on the heated imaging table with continuous
monitoring of vital signs. After visualization of the bladder with the Vevo 700H small animal imaging platform the skin was perforated with a 30G
needle. B. Ultrasound visualisation of normal mouse bladder in sagittal section with typical dimensions indicated (lumen dimensions 4.466.5 mm;
wall thickness 0.25 mm).
doi:10.1371/journal.pone.0059536.g001
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Intratumoral virus-injection. To demonstrate the poten-
tial for ultrasound guided percutaneous intratumoral injection of
treatment agents into established xenografts, we injected
oncolytic virus (VSV) into UM-UC3 luc xenografts on day 22
after inoculation. Tumor burden as determined by BLI and
ultrasound was used to divide the animals into two relatively
equal groups. The tumors were visualized longitudinally by
ultrasound and a 30G needle was inserted in the center of the
tumor [Fig. 3A]. VSV (1.05610
7 pfu) suspended in 25 mL PBS
was injected in 7 mice, and PBS alone was injected in the
control group (n=7).
Systemic chemotherapy. To demonstrate the potential for
in vivo real-time monitoring of xenograft perfusion, we treated
UM-UC13 luc tumor-bearing mice with cytotoxic chemotherapy.
On day 28 after inoculation, the mice were divided into two equal
groups based on tumor burden determined by ultrasound and
BLI. Eight animals received intraperitoneal gemcitabine (120 mg/
kg bodyweight; SANDOZ, Boucherville, QC, Canada) on day 30
and 35 as well as cisplatin (2.5 mg/kg bodyweight; Hospira, Saint-
Laurent, QC, Canada) on day 31 and 36. An equivalent volume of
PBS was injected at the same time points in the control animals
(n=7).
Histology
UM-UC3 luc, UM-UC1 luc and UM-UC13 luc xenografts
were harvested after 24, 28 and 37 days, respectively. At
necropsy, the pelvis, retroperitoneum, liver and lungs were
carefully inspected for possible metastasis, and any suspicious
tissue was removed. This tissue and the whole bladders were
fixed in formalin, embedded in paraffin and cut in 4-mm
sections which were stained with haematoxylin and eosin
(H&E). Depth of tumor invasion was determined by a pathol-
ogist (LF). For UM-UC3 tumors a T stage was applied
according to 7
th edition of the American Joint Committee on
Cancer/International Union Against Cancer (AJCC/UICC)
TNM classification [25].
Detection of apoptotic cells by the TUNEL (Terminal
deoxynucleotidyl transferase dUTP nick end labeling) technique
was performed using Terminal transferase (#03333566001,
Roche Applied Science, Indianapolis, IN, USA), dATP (D4788,
Sigma-Aldrich, St. Louis, MO, USA) and DIG-11-dUTP
(#1558706, Roche Applied Science). Using polyclonal rabbit
antibody against the G protein of VSV (VSV-G; 1:300, ab1874,
Abcam, Cambridge, MA, USA) immunohistochemical staining
was conducted by the Ventana autostainer model Discover XT
(Ventana Medical System, Tuscon, AZ, USA) with an enzyme-
labeled biotin streptavidin system and solvent-resistant 3,30-
diaminobenyidine Map kit. All samples were subsequently
analysed by a pathologist (LF) and the percentage of immunoex-
pression for VSV-G and staining for TUNEL was detected at
2006magnifications.
Statistical Analysis
For statistical analyses, the mean bioluminescence and tumor
volumes with their standard deviations were determined. The
significance of differences was measured by Student’s t test
(GraphPad Software Inc., San Diego, CA, USA) and P,0.05
was considered significant. Regression plots were used to
describe the correlation between bioluminescence and volume.
Figure 2. Inoculation of tumor cells. A. Detection of the needle on the ultrasound screen. B. Perforation of the skin and abdominal wall muscles.
C. Needle insertion into the bladder wall without penetration of the mucosa. D. Injection of PBS (50 ml) between the muscular layer and the mucosa.
E. Guidance of second needle into the artificially created space. F. Injection of tumor cells suspended in MatrigelH.
doi:10.1371/journal.pone.0059536.g002
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PLOS ONE | www.plosone.org 4 March 2013 | Volume 8 | Issue 3 | e59536Figure 3. Ultrasound-guided intratumoral injection of treatment agents. A. The xenografts were visualized by ultrasound and either VSV
(1.05610
7 pfu) dissolved in 25 ml PBS or PBS alone was injected through a 30G needle into the center of the tumor. B. 48 h after injection of VSV, all
xenograft tumors showed positive staining for VSV-G around the injection site which correlated to TUNEL staining. C. VSV-G and TUNEL staining were
negative after PBS injection alone.
doi:10.1371/journal.pone.0059536.g003
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Tumor Cell Inoculation
Ultrasound-guided tumor cell inoculation was successfully
performed in 50 animals (UM-UC1 luc 20 animals, UM-UC3
luc 15 animals and UM-UC13 luc 15 animals) [Table 1]. The
typical experimental set-up and representative ultrasound images
and dimensions of the murine bladder are depicted in Fig. 1. The
steps of inoculation are shown in Fig. 2. The mean time per
procedure (mounting of mice on the table until finished injection)
could be decreased from 7.763.7 min for the first group (UM-
UC3 luc) to 3.461.6 min for the third group (UM-UC1 luc). None
of the animals suffered any complication during the procedure.
Injection of agarose gel demonstrated that the inoculation was
strictly located between the lamina propria and the tunica
muscularis [Fig. 4].
Xenograft Growth Monitoring
All 50 animals showed detectable tumor in the anterior bladder
wall on ultrasound on the 4
th day after inoculation. The start and
Table 1. Percutaneous tumor cell injection – procedure, complications and growth.
Inoculated cell line UM-UC1 luc UM-UC3 luc UM-UC13 luc
Number of mice 50
20 15 15
Anesthesia Isoflurane Isoflurane Isoflurane
Time per animal, min 3.4 (+/21.6) 7.7 (+/23.7) 6.8 (+/22.9)
Anesthesia related deaths 00 0
Volume injected, mL 40 50 50
Cell count, absolute 3.6610
5 6610
5 5.5610
5
Tumor incidence 49 (98%)
20 (100%) 14 (93%) 15 (100%)
Extravesical tumor growth 2 (10%) – –
Intraperitoneal dissemination – 1 (7%) –
Lymph node metastasis – 3 (20%) 9 (60%)
Follow up (days) 28 22 [before treatment] 28 [before treatment]
Tumor volume (mL) day 4 11.6 (61.3) 12.5 (61.7) 14.4 (61.3)
end of follow up 394.6 (672.4) 288.7 (666.1) 78.3 (613.4)
Tumor luminescence (Photons/sec) day 4 4.6610
8 (69.4610
7)2 . 0 610
8 (63.7610
7) 5.8610
8 (61.3610
8)
end of follow up 1.9610
10 (64.0610
9)1 . 4 610
10 (62.3610
9) 1.5610
10 (61.9610
9)
doi:10.1371/journal.pone.0059536.t001
Figure 4. Intramural injection of agarose. The sagittal H&E section of a whole murine bladder demonstrates a layer of gel strictly in the lamina
propria between mucosa and the muscularis propria.
doi:10.1371/journal.pone.0059536.g004
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PLOS ONE | www.plosone.org 6 March 2013 | Volume 8 | Issue 3 | e59536Figure 5. Longitudinal imaging of xenograft growth. Tumor growth was measured at regular time intervals by: A. bioluminescence imaging,
and B. ultrasound. C. Correlation of bioluminescence and xenograft volume for all three cell lines. D. H&E section of a representative UM-UC1 luc
xenograft demonstrating invasive growth into the muscle (*) without invasion into adjacent organs. All tumors originated from the anterior bladder
wall and often occupied most of the bladder lumen without infiltrating the posterior wall (**).
doi:10.1371/journal.pone.0059536.g005
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of UM-UC3 luc, one mouse showed intraperitoneal tumor
dissemination and one tumor involuted after day 7. Similar
patterns were seen with BLI. All mice had detectable luminescence
on the 4
th day, and this increased steadily in all but one mouse.
The overall tumor uptake rate was 98%. These findings were
confirmed at the time of necropsy.
During tumor growth [Fig. 5A, 5B] the ratio between entire
tumor volume and BLI was not stable but variable depending on
the time after tumor cell inoculation and the entire tumor volume
itself. Although there had been a trend towards better correlation
over the time course (R
2=0.75, 0.82 and 0.92 for UM-UC1 luc at
day 16, UM-UC3 luc at day 19 and UM-UC13 luc at day 34
respectively [Fig. 5C]), a drastic decline of the luminescence per
mL tumor volume was noticed at high tumor volumes (data not
shown).We have previously demonstrated a role for hypoxia and
necrosis in this correlation [17].
Three mice (two UM-UC1 luc and one UM-UC3 luc) were
sacrificed for humane reasons related to excessive tumor burden
before the end of planned follow-up.
Histology
Examination of the xenografts on H&E sections demonstrated
that all tumors were invasive into muscle and some into perivesical
fat, but there was no evidence of invasion into adjacent organs
[Fig. 5D]. None of the tumors grew through the lamina propria
into the bladder lumen. Retroperitoneal lymphadenopathy was
noted in 60% of UM-UC13 luc and 20% of UM-UC3 luc
xenografts. This was confirmed by H&E staining (data not shown).
TNM staging was exemplary performed for all UM-UC3 luc
tumors by histological analysis of the primary tumors and
retroperitoneal lymph nodes, as well as macroscopic analysis of
liver and lungs [Table 2].
After intratumoral injection of VSV into UM-UC3 luc
xenografts [Fig. 3A], all 7 tumors showed positive staining for
VSV-G. The same areas of the tumors staining for VSV-G also
demonstrated staining in the TUNEL assay [Fig. 3B]. In contrast,
VSV-G staining was negative for xenografts treated with PBS at
the negative control [Fig. 3C].
Response to Chemotherapy
The mice bearing UM-UC13 luc tumors showed a remarkable
response to the combination of gemcitabine and cisplatin. The
median tumor volume significantly decreased from 48.6 mL( 67.7)
to 25.3 mL( 65.8) after 7 days of therapy, whereas it increased
from 48.8 mL( 614.8) to 114.5 mL( 626.8) in the control group
[Fig. 6A].
The perfusion of the xenograft tumor was measured before and
after administration of systemic chemotherapy with non-specific
microbubbles. Chemotherapy led to a decrease in the perfusion
rate (Contrast Percent Area) from 84% to 66%, whereas the same
parameter remained constant after treatment with PBS alone
(79% vs. 77%) [Fig. 6B].
Discussion
The existence of reliable animal models is a basic requirement
in oncologic research for the in vivo investigation of tumor biology
and the testing of novel antineoplastic treatment strategies. Despite
the existence of reproducible syngeneic [11] and transgenic [12]
orthotopic tumor models of bladder cancer, they are not widely
used due to both inherent limitations (e.g. questionable applica-
bility of syngeneic models of murine bladder cancer to human
disease) and complexity of the models, as well as the intensity of
associated resource utilization. Orthotopic xenograft models have
proven to offer the most flexibility (in terms of selection of cell
lines) and have the most practical utility, and therefore remain the
gold standard for in vivo modeling of bladder cancer [7,8].
In this work, we have generated a novel in vivo model of
orthotopic bladder cancer xenografts via the inoculation of human
bladder cancer cells into the murine bladder and have shown it to
be highly reproducible. Tumors were established in 98% of
inoculated mice using three different human cell lines. Due to
excellent optical resolution, the tumor cells can be inoculated by
high precision strictly into the anterior bladder wall, thus reducing
the rate of obstructive complications and allowing longer growth
and treatment periods. Furthermore, the time per inoculation is
short in comparison to existing models, and decreases rapidly with
additional experience. The single observed complication was an
intraperitoneal tumor cell dissemination which occurred in one of
the first animals injected and can be attributed to the injection of
too large a volume relative to the size of the animal. This was
supported by the fact that reducing the volume of injection from
50 to 40 mL resulted in no further complications.
Our model is a modification of the orthotopic model previously
described by Dinney et al. [10]. We believe that ultrasound-guided
tumor inoculation enhances this model due to its ease, rapidity,
accuracy and decreased degree of invasiveness. The latter factor is
not only one of animal welfare, but may also contribute to
reproducibility of experiments by decreasing confounding surgical
complications. The accuracy of the standard intramural injection
through a laparotomy is limited by the ability to determine exact
needle placement at the time of injection. The shape and
distribution of the bleb in the bladder wall after injection will
often confirm correct location, but there is no a priori confirma-
tion before the cells are injected. This means that a certain
proportion of mice will have cells injected into the lumen of the
bladder or spilled on the serosal surface of the bladder. With the
ultrasound technique, a space is created submucosally in the
bladder wall with saline, which carries no risk of spillage, and the
subsequent tumor cell inoculation easily follows into the same
space under direct visualization.
Monitoring tumor volume by ultrasound augments the in-
formation gained by BLI in the orthotopic xenograft model. While
BLI has become an integral component of tumor detection and
growth analysis, it does not always correlate well with tumor
volume. We have previously shown in the orthotopic xenograft
Table 2. TNM Classification of UM-UC3 luc xenograft tumors.
n%
T-Stage pTa 0 (0%)
pT1 0 (0%)
pT2a 5 (33%)
pT2b 5 (33%)
pT3a 4 (27%)
pT3b 1 (7%)
pT4 0 (0%)
Lymph nodes N+ 3 (20%)
N2 12 (80%)
Metastasis M+ 1 (7%)
M2 14 (93%)
doi:10.1371/journal.pone.0059536.t002
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between volume and luminescence [17], and the same is
presumably responsible for the disparities shown here. This is
particularly true in larger tumors [26], whereas early after
inoculation ultrasound size may be inaccurate due to the volume
of injected fluid, the surrounding tissue edema, and the fact that
only a proportion of injected cells survive and grow.
An additional advantage of the ultrasound is the ability to inject
novel treatment agents directly into the tumor. Here we have
demonstrated the feasibility of intratumoral delivery of oncolytic
Figure 6. Treatment of xenograft tumors by chemotherapy. A. Mice bearing UM-UC13 luc tumors showed a remarkable decrease in tumor
volume after systemic therapy with a combination of gemcitabine and cisplatin starting on day #28 after inoculation, compared to PBS control
(**=P,0.01). B. Xenograft perfusion was measured by injection and ultrasound imaging of non-targeted microbubbles in UM-UC13 luc xenografts
before and 5 days after administration of control agent (PBS; left panel) or systemic chemotherapy (gemcitabine/cisplatin; right panel). Perfusion was
quantified as contrast percent area. Representative single results out of 4 measured animals per group are shown.
doi:10.1371/journal.pone.0059536.g006
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strategies for bladder cancer such as gene therapy or the
application of nanoparticles [27,28]. As an example of the
relevance of intratumoral injection in the treatment of human
cancers, the intratumoral injection of DNA plasmid has recently
been tested in the therapy of unresectable pancreatic cancers [29].
We have also demonstrated the ability to monitor tumor
vascularity during drug treatment, in this case traditional cytotoxic
chemotherapy. This ability will be particularly useful when
evaluating the response of tumors to novel therapeutics including
the development of resistance which may be reflected by a failure
to diminish vascularity.
The principal limitation of ultrasound-guided tumor inoculation
is the dependence on the ultrasound imaging platform, which may
not be readily accessible to many researchers. Furthermore, this
model requires familiarity with ultrasound imaging. On the other
hand, complex animal modeling of human cancers, just like
complex surgery on human patients, may best be performed by
centers of excellence through scientific collaborations.
Our model does not necessarily substitute for the intravesical
instillation of bladder cancer cell lines [9,30]. The intramural
model is superior to the intravesical model for most applications
because of the ability to use multiple different cell lines. The
intramural model, however, has no utility for testing novel
therapies delivered intravesically because the tumors do not
disrupt the urothelial surface (lamina propria) in the bladder
lumen, and drugs therefore do not easily penetrate into the tumor.
These tumors grow expansively away from the lumen of the
bladder so that drugs administered into the lumen of the bladder
cannot penetrate the full depth of the tumor. Furthermore, the
intramural model represents muscle invasive disease, which is
never treated with intravesical therapy in clinical practice. In the
intravesical tumor model, on the other hand, the tumor surface is
exposed in the bladder lumen and the tumor generally does not
grow beyond the lamina propria for several weeks [9], so that
drugs administered into the bladder lumen can adequately
penetrate the tumor. The most significant limitation to the
intravescial model, however, is its restriction to very few cell lines
which, even in the most experienced hands, grow in only an
unreliable fashion.
Conclusions
We have successfully developed a technique for ultrasound-
guided inoculation of orthotopic bladder cancer xenografts that
significantly enhances pre-existing models of bladder cancer. The
major advantages of this model lie in the rapidity and ease of
tumor inoculation as well as in the accuracy and reproducibility of
the model. Furthermore, we are able to monitor tumor volume
longitudinally with ultrasound, to measure in vivo tumor perfusion
with microbubble contrast agents, and to inject therapeutic agents
into the tumor under ultrasound guidance.
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